CliniMACS® TCRα/β Product Line

TCRα/β Product Line

The T cell receptor (TCR) is a heterodimer composed of two transmembrane glycoprotein chains, α and β. Both chains are members of the Ig superfamily and consist of a constant and a polymorphic variable region. The variable region of the TCRα/β is involved in recognition of antigenic peptides presented by the MHC complex of antigen-presenting cells. The TCRα/β is expressed on the majority of peripheral blood T cells. The Anti-TCRα/β antibody recognizes a common determinant of the TCRα/β-CD3 complex.
The CliniMACS
TCRα/β Product Line consists of murine anti-TCRα/β monoclonal antibodies conjugated to biotin.
One vial contains 7.5 mL sterile, non-pyrogenic solution.
The performance of the CliniMACS TCRα/β Product Line depends on the individual separation strategy. For information on respective capacities, refer to the CliniMACS User Manual or contact your local representative.
Please inquire about required CliniMACS System components and accessories.


The CliniMACS
System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485.
In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for
in vitro
use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans the national legislation and regulations - e.g., for the EU the Directive 2004/23/EC ("human tissues and cells"), or the Directive 2002/98/EC ("human blood and blood components") - must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System.
In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved as a Humanitarian Use Device (HUD), authorized by U.S. Federal law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this indication has not been demonstrated. Other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application, Investigational Device Exemption (IDE) or FDA approval.
CliniMACS GMP MicroBeads are for research use and
ex vivo
cell processing only.
CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use.


The CliniMACS TCRα/β Product Line was developed for the depletion of unwanted TCRα/β
T cells from human heterogeneous hematologic cell populations in combination with the CliniMACS System. This approach maintains the stem cells and immune effector cells, such as NK cells and TCRγ/δ
T cells, in the cellular product.
The CliniMACS TCRα/β Product Line can also be used in combination with the CliniMACS CD19 Reagent to additionally remove the CD19
B cells from the cellular product.
After labeling of TCRα/β
cells with CliniMACS TCRα/β-Biotin, CliniMACS Anti-Biotin Reagent is used for the magnetic depletion of TCRα/β
cells from the cellular product.
  • Selected references

    1. Schumm, M. et al. (2013) Depletion of T-cell receptor alpha/beta and CD19 positive cells from apheresis products with the CliniMACS device. Cytotherapy 15(10): 1253-1258
    2. Lang, P. et al. (2014) Blood 124: 852
    3. Kharya, G. et al. (2014) Haploidentical T-cell alpha beta receptor and CD19-depleted stem cell transplant for Wiskott-Aldrich syndrome. J. Allergy Clin. Immunol. 134: 1199-1201
    4. Bertaina, A. et al. (2014)
      HLA-haploidentical stem cell transplantation after removal of αβ
      T and B cells in children with nonmalignant disorders.
      Blood 124(5): 822-826
    5. Tumino, M. et al. (2014) Haploidentical TCR A/B and B-cell depleted hematopoietic SCT in pediatric SAA and aspergillosis. Bone Marrow Transplant. 49: 847
    6. Maschan, M. et al. (2014) Bone Marrow Transplant. 49: 381
    7. Haen, S. P. et al. (2013) Blood 122: 5475
    8. Prezioso, L. et al. (2013) Blood 122: 4609
  • Selected references

  • Certificates

    Please follow this
    to search for Certificates of Analysis (CoA) by lot number.
Product options: 2
SEK 39 630,00 
7.5 mL
SEK 22 950,00 

Related products

2 products available